Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Bladder-Saving cancer treatment trial seeks participants

NCT ID NCT07279597

Summary

This study is testing whether a combination of targeted drugs (toripalimab and RC48-ADC) plus radiation can effectively treat muscle-invasive bladder cancer while allowing patients to keep their bladder. The trial will enroll 45 adults with HER2-positive bladder cancer who have already had initial surgery and chemotherapy. Participants will receive the drug combination alongside radiation, followed by maintenance therapy for those who respond well.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.